Vaginal progesterone in menopause: Crinone® 4% in cyclical and constant combined regimens

Human Reproduction

Volumn 15, Issue SUPPL. 1, 2000, Pages 149-158

  De Ziegler, D ^a,b,d   Ferriani, R ^c   Moraes, L A M ^c   Bulletti, C ^a,d  

^a Groupement Hospitalier de l'Ouest Lemanique   (Switzerland)

^b Columbia Laboratories Inc ^*  (France)

^c Department of Obstetrics Gynecology ^*  (Brazil)

^d Hospital of Rimini   (Italy)

Author keywords

Constant combined; Menopause; Progesterone; Vaginal administration

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL VALERATE; ESTROGEN; PROGESTERONE;

ADULT; AGED; AMENORRHEA; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; PATIENT COMPLIANCE; SUSTAINED RELEASE PREPARATION; THICKNESS; TREATMENT OUTCOME; UTERUS BLEEDING;

EID: 0034100075     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.suppl_1.149     Document Type: Article

References (28)

1. Archer, D.F., Pickar, J.H. and Bottiglioni, F. (1994) Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet. Gynecol., 83, 686-692.
2. Barret-Connor, E. (1996) The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. Maturitas, 23, 227-234.
3. Bourgain, C., Devroey, P., Van Waesberghe, L. et al. (1990) Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum. Reprod., 5, 537-543.
4. Bulletti, C., de Ziegler, D., Flamigni, C. et al. (1997) Targeted drug delivery in gynaecology: the first uterine pass effect. Hum. Reprod., 12, 1073-1079.
5. Casanas-Roux, F., Nisolle, M., Marbaix, E. et al. (1996) Morphometric, immunohistological and three-dimensional evaluation of the endometrium of menopausal women treated by oestrogen and Crinone, a new slow-release vaginal progesterone. Hum. Reprod., 11, 357-363.
6. Chantilis, S.J., Zeitoun, K.M., Patel, S.I. et al. (1999) Use of Crinone® vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril., 72, 823-829.
7. Clisham, P.R., de Ziegler, D., Lozano, K. and Judd, H.L. (1991) Comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal women. Obstet. Gynecol., 77, 241-246.
8. de Ziegler, D., Bergeron, C., Cornel, C. et al. (1992) Effects of luteal estradiol on the secretory transformation of human endometrium and plasma gonadotropins. J. Clin. Endocrinol. Metab., 74, 322-331.
9. Fanchin, R., de Ziegler, D., Bergeron, C. et al. (1997) Transvaginal administration of progesterone: dose-response data support a first uterine pass effect. Obstet. Gynecol., 90, 396-401.
10. Grodstein, F., Stampfer, M.J., Manson, J.E. et al. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med., 335, 453-461.
11. Hahn, R.G. (1989) Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am. J. Obstet. Gynecol., 161, 1854-1858.
12. Hulley, S., Grady, D., Bush, T. et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc., 280, 605-613.
13. Jiang, C.W., Sarrel, P.M., Lindsay, D.C. et al. (1992) Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur. J. Pharmacol., 211, 163-167.
14. Jobanputra, K., Toner, J.P., Denoncourt, R. and Gibbons, W.E. (1999) Crinone 8% (90 mg) given once daily for progesterone replacement therapy in donor egg cycles. Fertil. Steril., 72, 980-984.
15. Lindsay, R., Bush, T.L., Grady, D. et al. (1996) Therapeutic controversy. Estrogen replacement in menopause. J. Clin. Endocrinol. Metab., 81, 3829-3838.
16. Lobo, R.A. (1992) The role of progestins in hormone replacement therapy. Am. J. Obstet. Gynecol., 166, 1997-2004.
17. Miles, R.A., Paulson, R.J., Lobo, R.A. et al. (1994) Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil. Steril., 62, 485-490.
18. Navot, D., Laufer, N., Kopolovic, J. et al. (1986) Artificially induced endometrial cycles and establishment of pregnancies in the absence of ovaries. N. Engl. J. Med., 314, 806-811.
19. Navot, D., Bergh, P.A., Williams, M. et al. (1991) An insight into early reproductive process through the in vivo model of ovum donation. J. Clin. Endocrinol. Metab., 72, 408-414.
20. Nilas, L and, Christiansen, C. (1996) The pathophysiology of peri-and postmenopausal bone loss. Br. J. Obstet. Gynaecol., 96, 580-587.
21. Panay, N. and Studd, J. (1997) Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum. Reprod., 13, 159-171.
22. Ravnikar, V.A. (1987) Compliance with hormone therapy. Am. J. Obstet. Gynecol., 156, 1332-1334.
23. Rosano, G.M.C., Sarrel, P.M., Chierchia, S.L. et al. (1996) Medroxyprogesterone acetate (MPA) but not natural progesterone (P) reverses the effect of estradiol 17β (E2) upon exercise induced myocardial ischemia. A double-blind cross-over study. [Abstract.] Circulation, 94 (Suppl.), I-18.
24. Rosenwaks, Z. (1987) Donor eggs: their application in modern reproductive technologies. Fertil. Steril., 47, 895-909.
25. Sherwin, B.B. (1991) The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J. Clin. Endocrinol. Metab., 72, 336-343.
26. Simón, J.A., Robinson, D.E., Andrews, M.C. et al. (1993) The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil. Steril., 60, 26-33.
27. Warren, M.P. and Shantha, S. (1999) Uses of progesterone in clinical practice. Int. J. Fertil. Womens Med., 44, 96-103.
28. Warren, M.P., Biller, B.M.K. and Shangold, M.M. (1999) A new clinical option for hormone replacement therapy in women with secondary amenorrhea: effects of cyclic administration of progesterone from the sustained release vaginal gel Crinone (4% and 8%) on endometrial morphologic features and withdrawal bleeding. Am. J. Obstet. Gynecol., 180, 42-48.